We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Cjc2.5

CJC-1295 Research

Mostly mechanism / observationalLimited safety

8 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most CJC-1295 studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from mixed-quality randomised trials published 2005–2026 with a typical study size of 11 participants.

Based on 8 studies · 1 RCT · 11 total participants

Confidence

Low

By outcome

GH / IGF-1 axis
Mostly mechanism / observational7 studies
Lean body mass & muscle growth
Mostly mechanism / observational3 studies
Safety profile
Too few graded studies1 study

Steady research

1 study in the last 5 years

200520152026

1RCT2006

Subcutaneous administration of CJC-1295 resulted in sustained, dose-dependent increases in GH and IGF-I levels in healthy adults and was safe and relatively well tolerated, particularly at doses of 30 or 60 microg/kg.

Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. · J Clin Endocrinol Metab (2006)

Two randomized, placebo-controlled, double-blind ascending-dose phase-1 trials in healthy adults aged 21-61 (28- and 49-day durations)
Single subcutaneous dose raised mean plasma GH 2- to 10-fold for ≥6 days and IGF-I 1.5- to 3-fold for 9-11 days; estimated half-life 5.8-8.1 days
After multiple doses, mean IGF-I stayed above baseline for up to 28 days, with evidence of a cumulative effect

View source

2Pilot2006

CJC-1295 increased trough and mean GH secretion and IGF-I production with preserved GH pulsatility.

Ionescu M, Frohman LA. · J Clin Endocrinol Metab (2006)

Healthy men aged 20-40 had overnight GH pulsatility sampled before and 1 week after a single 60 or 90 microg/kg subcutaneous CJC-1295 injection
GH pulse frequency and magnitude were unchanged, but basal (trough) GH rose markedly (7.5-fold), raising mean GH (~46%) and IGF-I (~45%)
No significant difference between the two doses; IGF-I increases did not correlate with GH-secretion parameters

View source

3Animal2005

These results led to the identification of CJC-1295 as a stable and active hGRF(1-29) analog with an extended plasma half-life.

Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. · Endocrinology (2005)

Three maleimido hGRF(1-29) derivatives were bioconjugated to human serum albumin and tested in vitro and in rats
All conjugates resisted dipeptidyl-peptidase-IV and stimulated GH secretion in cultured rat anterior-pituitary cells
CJC-1295 was the best compound (4-fold higher GH AUC vs hGRF(1-29)) and remained detectable in rat plasma beyond 72 h, bound to albumin

View source

4Animal2006

Treatment with once-daily administration of CJC-1295 is able to maintain normal body composition and growth in GHRHKO mice.

Alba M, Fintini D, Sagazio A, Lawrence B, Castaigne JP, Frohman LA, Salvatori R. · Am J Physiol Endocrinol Metab (2006)

GHRH-knockout mice were treated for 5 weeks with CJC-1295 every 24, 48 or 72 hours
Once-daily dosing normalized body weight and length; every-48/72-h dosing improved but did not fully normalize growth
Relative lean and subcutaneous fat mass were normal in all treated groups

View source

5Animal2009

Treatment of Br-M3-KO mice with CJC-1295, a synthetic GH-releasing hormone (GHRH) analog, rescued the growth deficit displayed by Br-M3-KO mice by restoring normal pituitary size and normal serum GH and IGF-1 levels.

Gautam D, Jeon J, Starost MF, Han SJ, Hamdan FF, Cui Y, Parlow AF, Gavrilova O, Szalayova I, Mezey E, Wess J. · Proc Natl Acad Sci U S A (2009)

Brain-specific M3-muscarinic-receptor knockout mice showed dwarfism with anterior-pituitary hypoplasia and low GH/prolactin
CJC-1295 treatment restored normal pituitary size and normal serum GH and IGF-1, rescuing the growth deficit
Used CJC-1295 as a pharmacological GHRH-axis probe to dissect somatotroph regulation

View source

6Review2026

CJC-1295 combined with ipamorelin showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss, but these findings are limited to animal studies.

Mayfield CK, Bolia IK, Feingold CL, Lin EH, Liu JN, Rick Hatch GF, Gamradt SC, Weber AE. · Am J Sports Med (2026)

Independent narrative review of popular injectable peptides (BPC-157, TB-4/TB-500, CJC-1295 + ipamorelin, tesamorelin, GHK-Cu) for orthopaedic/sports use
The only CJC-1295 efficacy signal cited is improved tetanic tension in a murine glucocorticoid-induced muscle-loss model — animal only
Stresses indications, dosing, frequency and duration remain unknown and that safety/efficacy research is needed before recommendations

View source

7Pilotn=11 · very small study2009

Serum GH and IGF-1 levels have been shown to increase with administration of GHRH or CJC-1295, a long-acting GHRH analog.

Sackmann-Sala L, Ding J, Frohman LA, Kopchick JJ. · Growth Horm IGF Res (2009)

Sera from 11 healthy young adult men before and one week after a single CJC-1295 injection were compared by 2-D gel electrophoresis and mass spectrometry
Identified candidate GH/IGF-1 biomarkers: decreased apolipoprotein A1 and transthyretin isoforms; increased beta-hemoglobin and albumin/immunoglobulin fragments
A linear relationship was seen between one immunoglobulin/albumin-fragment spot and IGF-1 levels

View source

8Review2010

CJC-1295 is a releasing factor for growth hormone and is therefore considered a Prohibited Substance under Section S2 of the WADA Prohibited List.

Henninge J, Pepaj M, Hullstein I, Hemmersbach P. · Drug Test Anal (2010)

Norwegian doping laboratory analyzed an unknown illicit pharmaceutical preparation by LC-HRMS/MS
Identified a 29-amino-acid C-terminally amidated peptide whose sequence is consistent with the marketed peptide CJC-1295
States CJC-1295 is a WADA-prohibited substance (Section S2) with potential performance-enhancing effects

View source

View in Research Library

CJC-1295 Research

Mostly mechanism / observational

Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults.

Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.

Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog.

Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse.

Neuronal M3 muscarinic acetylcholine receptors are essential for somatotroph proliferation and normal somatic growth.

Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.

Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects.

Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation.